Cantor Fitzgerald Believes Jazz Pharmaceuticals (NASDAQ: JAZZ) Still Has Room to Grow

By Carrie Williams

In a report released today, William Tanner from Cantor Fitzgerald reiterated a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), with a price target of $197. The company’s shares closed yesterday at $158.80, close to its 52-week high of $163.75.

Tanner wrote:

“Meetings highlight view that late-stage assets are underappreciated. We hosted meetings with the CEO in the Midwest last week. Investors he met with expressed interest in Xyrem, of course, but the bulk of the questions centered around the pipeline. A common theme was that JZP-110 may be underestimated by the Street. We also spoke with some investors who seem to be gaining appreciation for the potential of the low-sodium oxybate formulations. Vyxeos approval could be around the corner. The PDUFA date for Vyxeos is September 30, and management commented that Breakthrough-designated drugs have been approved before the statutory date.”

According to, Tanner is a 4-star analyst with an average return of 12.5% and a 61.7% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.

Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $184.08.

Jazz Pharmaceuticals’ market cap is currently $9.53B and has a P/E ratio of 24.32. The company has a book value ratio of 4.8048.

Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock. Last month, Bruce Cozadd, the Chairman & CEO of JAZZ sold 30,000 shares for a total of $4,603,943.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products. It has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.